The Russian Federal Medical-Biological Agency expects approval for two new vaccines against glioblastoma by 2026. Head Veronika Skvortsova announced this in an interview with RIA Novosti.
The first vaccine, a peptide-based one named "Gliopept," is set for approval by year-end. The second, an mRNA vaccine called "Glioma," will follow.
Oncologist Yevgeny Cheremushkin noted that glioblastoma is an aggressive cancer often discovered accidentally. Symptoms include vision, hearing, and smell deterioration, headaches, and coordination issues.
